Sangamo BioSciences | SGMO


Peers Price Chg Day Year Date
Alnylam Pharmaceuticals 452.00 -1.54 -0.34% 83.16% Sep/05
Amgen 283.64 3.54 1.26% -11.49% Sep/05
Tectonic Therapeutic 16.80 -0.47 -2.72% -8.50% Sep/05
Bayer 28.16 -0.42 -1.47% -1.83% Sep/06
Biogen 140.67 0.73 0.52% -30.02% Sep/05
BioMarin Pharmaceutical 57.77 1.02 1.80% -31.29% Sep/05
Clal Biotechnology 32.00 0.40 1.27% -17.53% Sep/04
Compugen 479.60 -2.50 -0.52% -33.09% Sep/04
Cipla 1,553.40 -24.40 -1.55% -3.58% Sep/05
CSL 209.25 -1.60 -0.76% -31.17% Sep/05
Gilead Sciences 115.05 2.28 2.02% 46.10% Sep/05
Grifols 10.13 0.23 2.32% 19.32% Sep/05
GlaxoSmithKline 1,476.00 7.00 0.48% -10.63% Sep/05
Ionis Pharmaceuticals 61.23 1.88 3.17% 30.58% Sep/05
J&J 178.43 -0.33 -0.18% 8.51% Sep/05
Merck 84.71 0.66 0.79% -28.14% Sep/05
Novartis 103.98 0.06 0.06% 5.46% Sep/05
Pfizer 24.88 0.34 1.39% -12.95% Sep/05
Ultragenyx Pharmaceutical 31.82 0.54 1.73% -42.40% Sep/05
Roche Holding 274.20 -1.50 -0.54% 2.62% Sep/06
Sanofi 79.50 0.54 0.68% -24.83% Sep/06
Sarepta Therapeutics 18.71 0.25 1.35% -85.49% Sep/05
Vertex Pharmaceuticals 396.12 -0.81 -0.20% -15.39% Sep/05
Alaunos Therapeutics 2.16 0 0% -10.74% Sep/05

Indexes Price Day Year Date
USND 21700 -7.31 -0.03% 30.01% Sep/05
US2000 2391 11.44 0.48% 14.33% Sep/05

Sangamo BioSciences traded at $0.56 this Tuesday April 9th, decreasing $0.002 or 0.32 percent since the previous trading session. Looking back, over the last four weeks, Sangamo BioSciences lost 36.13 percent. Over the last 12 months, its price fell by 62.17 percent. Looking ahead, we forecast Sangamo BioSciences to be priced at 0.56 by the end of this quarter and at 0.55 in one year, according to Trading Economics global macro models projections and analysts expectations.

Sangamo Therapeutics, Inc. is a clinical-stage genomic medicine company. The Company is focused on translating science into medicines that transform the lives of patients with serious diseases. Its product candidates include Giroctocogene fitelparvovec (SB-525), ST-920, SAR445136, ST-400 and TX200. Its SB-525, is a lead product candidate, a gene therapy for the treatment of hemophilia A. Its ST-920, is a gene therapy product candidate for the treatment of fabry disease. SAR445136, is its cell therapy product candidate for the treatment of sickle cell disease (SCD). Its ST-400 is a cell therapy product candidate for the treatment of transfusion dependent beta thalassemia. Its TX200, is a chimeric antigen receptor (CAR), engineered regulatory T cell (CAR-Treg), cell therapy product candidate for the treatment of HLA-A2 mismatched kidney transplant rejection.